The Indian Pharmaceutical Market (IPM) reported value growth of 11.0 per cent and unit growth of 1.3 per cent in February 2026, with several therapy segments posting strong gains in both value and volume. Data from Pharmarack indicates that six therapy categories stood out during the month for delivering the highest value growth alongside notable unit expansion.
Among them, Vaccines emerged as the fastest-growing therapy segment. The category reported sales of Rs 220 crore, contributing 1 per cent to the IPM. It recorded a value growth of 30.1 per cent, while unit growth surged 44.0 per cent, making it the strongest performer across therapy areas for the month.
The Others category also posted strong growth momentum. The segment generated sales of Rs 162 crore, accounting for 1 per cent of the market, while registering value growth of 24.5 per cent and unit growth of 23.1 per cent.
Urology therapies continued to expand steadily, reporting sales of Rs 370 crore and contributing 2 per cent to the IPM. The segment recorded value growth of 14.5 per cent, supported by unit growth of 6.0 per cent during the month.
The Anti-neoplastics segment, representing oncology therapies, also delivered strong gains. The therapy recorded sales of Rs 501 crore, accounting for 2 per cent market share, and posted value growth of 12.9 per cent with a significant unit growth of 21.1 per cent.
Among large chronic therapy areas, Anti-diabetic therapies reported sales of Rs 1,982 crore, contributing 10 per cent to the IPM. The segment registered value growth of 15.5 per cent along with unit growth of 4.4 per cent, reflecting sustained demand in diabetes management.
Another major therapy segment showing strong growth was Cardiac therapies. The category recorded sales of Rs 2,937 crore, accounting for 14 per cent of the IPM, and posted value growth of 14.8 per cent with unit growth of 5.8 per cent, maintaining its position as the largest therapy area in the market.
Overall, the vaccines, oncology, urology, anti-diabetic, cardiac, and others segments emerged as key growth drivers in February 2026, highlighting continued momentum in both specialty and chronic therapy areas within the Indian pharmaceutical market.
